I n stroke patients, glucose values above 144 mg/dL are associated with a 3-fold increase in mortality and are related to a higher degree of permanent disability. 1 Plasma glucose is an important determinant of brain injury in experimental models of focal cerebral ischemia/reperfusion. 2 Yet, the actual mechanisms involved in these negative effects remain unclarified. Although much attention was focused in the past on the worsening effect of increased lactate production, 3, 4 extracellular lactate accumulation is not a crucial determinant of brain injury. 5 Also, glucose per se, but not lactate, in combination with acidosis mediates the detrimental hyperglycemic effect in organotypic hippocampal slices. 6 Among other putative worsening effects of hyperglycemia is the reported impaired cerebral blood flow restoration at reperfusion. 7, 8 However, no effect of hyperglycemia on cerebral blood flow and still a bad neuropathological outcome has also been reported. 9 Hyperglycemia dramatically enhances neutrophil infiltration in brain after transient focal ischemia. 10 Also, an exaggerated leukocyte-endothelial cell adhesion has been described after mesenterium ischemia in diabetes mellitus. 11 Therefore, hyperglycemia-enhanced inflammatory response to ischemia/reperfusion might contribute to exacerbate the ischemic injury. 10 More recently, the view is growing that hyperglycemiainduced release of glucocorticoids is responsible for the worsening effect of this condition, as shown in an experimental model of global ischemia in rats. [12] [13] [14] Whether glucocorticoids are the main cause of aggravation of ischemic damage by hyperglycemia in transient focal ischemia has not been addressed.
Furthermore, hyperglycemia activates the hexosamine pathway leading to increased O-linked glycosylation, 15 which depends on the action of specific catalytic enzymes. 16 O-glycosylation has been identified as a mediator of pancreatic islet injury induced by hyperglycemia and streptotozin, 17, 18 and in the development of glucose-induced insulin resistance. 19 Whether O-glycosylation occurs in the ischemic brain after acute hyperglycemia has not been investigated.
Methods

Transient Focal Cerebral Ischemia
Adult male Sprague-Dawley rats (Harlan Interfauna Ibèrica SL; Sant Feliu de Codines, Spain; nϭ217) weighing 280 to 320 g were used. Rats had free access to food and water. Animal experiments were conducted with approval of the Ethical Committee of our Institution. Ischemia was produced by 1-hour intraluminal occlusion of the right middle cerebral artery (MCAO) with reperfusion (nϭ196), as reported. 20 Sham-operated (nϭ10) and nonoperated rats (nϭ11) were used as controls.
Induction of Acute Hyperglycemia
Hyperglycemia was induced by IP injection of dextrose (Sigma; 25%; 2.5 mL) 30 minutes before MCAO (nϭ19). 10 Normoglycemic rats received vehicle (water; nϭ22). Blood samples were withdrawn: before treatment (basal), immediately after MCAO, and at reperfusion, to measure glucose levels (Accu-Check Sensor Glucometer, Roche Diagnostics).
Inhibition of Corticosterone Synthesis
Rats received metyrapone (Sigma; 100 mg/kg; nϭ40) or vehicle (nϭ52) IP 1 hour before MCAO. Rats were randomly assigned to hyperglycemia (nϭ47) or normoglycemia (nϭ45) and were accordingly given dextrose or vehicle 30 minutes after metyrapone. Arterial blood corticosterone levels were measured with a Radioimmunoassay assay 21 at different points: basal (before treatment), at the moment of dextrose/vehicle administration, after MCAO, and at reperfusion.
Induction of Neutropenia
Rats received either saline (nϭ11) or vinblastine (Sigma; 0.5 mg/kg bw; nϭ11), and were given antibiotics, as reported. 22 Arterial blood samples were withdrawn to count neutrophils with a blood cell counter (Pentra 120DX, SPS Evolution, HORIBA ABX) at day 0 and 4 days later, before induction of ischemia. Thirty minutes before MCAO all rats received dextrose to induce hyperglycemia. Rats were killed after 24 hours of reperfusion.
MRI
At 12 hours after MCAO, normoglycemic (nϭ14) and hyperglycemic (nϭ23) rats, with or without metyrapone (nϭ11 and 12, respectively), were anesthetized (ketamine) and introduced in a 1.5T Signa Horizon LX magnet (General Electrics) provided with a QDWRIST coil. Adquisition parameters for diffusion-weighted imaging were echo timeϭ91 ms, repetition timeϭ10 000 ms, field-of-viewϭ8ϫ8 cm, matrixϭ128ϫ128, number of excitationsϭ4, slice thicknessϭ2 mm, spacingϭ0.5 mm. b values were 0 and 1000 s/mm 2 . Apparent diffusion coefficient maps were produced with Functool2 software (GE), and the threshold 23 was set at 500ϫ10 Ϫ6 mm 2 s Ϫ1 to calculate lesion volume.
Assessment of Brain Damage
A simple neurological test in a 0 (normal) to 9 (highest handicap) point-scale was carried out at 24 hours. 24 Rats were anesthetized and killed by decapitation. The brain was removed and sliced in The normoglycemic (N) and hyperglycemic (H) groups that also received Metyrapone are identified as NϩM and HϩM, respectively. Mean blood pressure, rectal temperature, pO 2 , pCO 2 and pH were monitored during MCAO. Values are expressed as the meanϮSEM of n rats per group. Data were analysed for statistical differences with 1-way ANOVA, followed by Bonferroni post-hoc analysis. ***PϽ0.001 vs normoglycemic; ###PϽ0.001 vs normoglycemicϩmetyrapone. No differences were found between the hyperglycemic groups receiving or not metyrapone. Hyperglycemia was induced with dextrose in all animals at day 4 after treatment with Vinblastine or vehicle. Mean blood pressure, rectal temperature, pO 2 , pCO 2 and pH were monitored during MCAO. Values are expressed as the meanϮSEM. Figure 1 . Hyperglycemia impairs ischemic brain damage, which is not prevented by metyrapone. A, Plasma corticosterone concentration was measured at times: 0 (basal), 30 minutes (hyperglycemia induction), 60 minutes (MCAO), and 120 minutes (immediately after reperfusion). Measures were carried out in 4 rat groups (nϭ2 to 4 per group) that were all subjected to ischemia: normoglycemic (N), hyperglycemic (H), normoglycemicϩmetyrapone (NϩMety), and hyperglycemicϩmetyrapone (HϩMety). Plasma corticosterone levels increase after ischemia in hyperglycemic rats in relation to basal (1-way ANOVA; *PϽ0.05). Comparison of the time course between groups (2-way ANOVA) shows higher corticosterone concentrations in hyperglycemic than in normoglycemic (&PϽ0.05), and lower values in metyrapone groups (#PϽ0.05). B, At MCAO onset (nϭ15 to 22 rats per group), plasma corticosterone concentration is significantly reduced by metyrapone (PϽ0.001). C, Infarct volume is higher in H than in N (***PϽ0.001). Metyrapone has a nonsignificant tendency to reduce infarct volume in hyperglycemia, but the volume is still higher than in corresponding controls (NϩM; #PϽ0.05 
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Myeloperoxidase Assay
At 24 hours, rats were anesthetized, perfused through the heart with saline, and killed. Brain regions (parietal cortex and striatum) ipsilateral and contralateral to MCAO were dissected out, frozen, and kept at Ϫ80°C. Myeloperoxidase (MPO) was extracted from tissue. 22 Change in absorbance at 460 nm was measured at 37°C with a spectrophotometer (Ultrospec 3000; Amersham Pharmacia Biotech).
Measures were expressed as units per mg of protein (Bradford assay; Bio-Rad, Hercules).
Gel Zymography
Brain tissue was obtained as described above. Samples were subjected to detergent extraction and purification of gelatinolytic activity, and zymography was carried out. 22 A mixture of matrix metalloproteinase-9 (MMP-9) and MMP-2 (CC073, Chemicon) was used as a gelatinase standard. Images of the gels were obtained (DC-120 camera, Kodak) to analyze the intensity of the bands (Kds1D software, Kodak).
O-Glycosylation
Brain tissue was obtained at 24 hours for Western blot analysis. 22 O-glycosylation was studied with a mouse monoclonal antibody against O-linked N-Acetylglucosamine, clone RL2 (Affinity Bioreagents) diluted 1:500. A rabbit polyclonal antibody against actin (Sigma) was used (1:10 000) as a loading control. Band intensity was measured (Kds1D software, Kodak), and expressed as the ratio to the corresponding actin band intensity to correct for any differences in protein loading between lanes.
Statistical Analyses
Comparisons between 2 groups were made with the Student t test. One-way ANOVA was used for comparisons between Ͼ2 groups. The effect of treatments at different time points was analyzed with 2-way ANOVA. Bonferroni test was used for post-hoc analyses.
Samples not conforming normality were analyzed with nonparametric Kruskal-Wallis test followed by Dunn Multiple Comparison test.
Results
Plasma Corticosteroids Do Not Account for Hyperglycemia-Enhanced Ischemic Brain Damage
The synthesis of corticosterone, which is the main plasma corticosteroid in rodents, was inhibited by treating the rats with metyrapone 30 minutes before bringing on hyperglycemia. We induced ischemia in 4 groups of rats: normoglycemic, hyperglycemic, metyrapone-normoglycemic, and metyraponehyperglycemic. Table 1 shows the physiological parameters of rats. Plasma corticosterone levels increased after ischemia under hyperglycemia in relation to basal (PϽ0.05; Figure 1A ), and were higher in hyperglycemic than in normoglycemic rats (PϽ0.05). Metyrapone successfully prevented increases in plasma corticosterone levels during and after ischemia in normoglycemic and hyperglycemic rats (PϽ0.05; Figure 1A and 1B). Hyperglycemia significantly (PϽ0.01) increased infarct volume at 24 hours ( Figure 1C ). This was attributable to larger (PϽ0.001) cortical ( Figure 1D ), but not subcortical ( Figure 1E ), infarct. Metyrapone tended to reduce infarct volume in hyperglycemic rats ( Figure 1C) , particularly in the cortex ( Figure 1D ). However, differences between hyperglycemic rats treated or not with metyrapone were not statistically significant, and infarct volume was still higher in hyperglycemic rats treated with metyrapone than in control normoglycemic rats (PϽ0.05). Also, hyperglycemia worsened the neurological score (PϽ0.01; Figure 1F ), and this was not prevented by metyrapone ( Figure 1F) .
MRI studies at 12 hours confirmed the hyperglycemiaincreased ischemic damage (PϽ0.001). Metyrapone again tended to reduce apparent diffusion coefficient lesion volume, but difference was not statistically significant, and the volume was significantly higher in metyrapone-treated hyperglycemic rats than in normoglycemic rats (PϽ0.05; Figure 2A and 2B).
Ischemia induced neutrophil infiltration (PϽ0.001), as assessed with the MPO assay, and this effect was exacerbated by hyperglycemia (PϽ0.001; Figure 3A ). This enhanced MPO activity was not significantly reduced by metyrapone ( Figure 3B ). Brain MMP-9 showed 2 bands (band aϭ95 kDa, and band bϭ88 kDa), which intensity increased at 24 hours postischemia in normoglycemic rats, as reported. 22, 25 Hyperglycemia significantly (PϽ0.01) increased band a intensity ( Figure  3C and 3D), but did not affect band b (Figure 3C and 3E). Metyrapone did not significantly reduce the hyperglycemiainduced MMP-9 increase in band a intensity ( Figure 3D and 3E), and did not affect band b either ( Figure 3D and 3F). Hyperglycemia worsens the cortical diffusion-weighted imaging alteration and this is not attributable to corticosterone. A, diffusion-weighted imaging and corresponding TTC images obtained at 12 hours of reperfusion showing representative rats for the different treatment groups: normoglycemia (N; nϭ14), hyperglycemia (H; nϭ12), hyperglycemiaϩmetyrapone (HϩMety; nϭ11). Cortical hyperintensities are more manifest in hyperglycemic groups than in the normoglycemic group. B, Cortical apparent diffusion coefficient lesion volume is higher in hyperglycemic than in normoglycemic groups (***PϽ0.001). Hyperglycemic rats treated with metyrapone show apparent diffusion coefficient lesion volume higher than controls (*PϽ0.05), but a marked tendency to lesion attenuation compared with hyperglycemic rats not receiving metyrapone. NS means nonsignificant differences between the indicated groups.
Hyperglycemia Enhances Neutrophil Infiltration, but This Effect Does Not Contribute to the Exacerbated Ischemic Brain Damage at 24 Hours
The physiological parameters of rats are shown in Table 2 . Vinblastine significantly reduced blood neutrophil counts (PϽ0.001). Accordingly, this treatment successfully reduced postischemic brain MPO in hyperglycemic rats (PϽ0.05; Figure 4A ). However, it did not reduce infarct volume at 24 hours ( Figure 4B ), and the neurological score was not ameliorated either (meanϮSDϭ6.2Ϯ1.9 and 5.5Ϯ1.6 in control and neutropenic rats, respectively). Neutropenia reduced (PϽ0.01) brain MMP-9 band a in hyperglycemic rats ( Figure  4C ), whereas MMP-9 band b ( Figure 4F ) was unmodified by treatments. The cerebral MMP-9 band a content was correlated with the corresponding MPO activity (PϽ0.001; Figure 4E ).
Hyperglycemia Induces Protein Glycosylation in the Ischemic Brain
The amount of O-glycoproteins was increased in the brain of hyperglycemic rats ( Figure 5A ). Quantification of one of the major O-glycoproteins showed a significant increase (PϽ0.05) in the ischemic brain in hyperglycemia ( Figure 5B ). Hyperglycemia increases postischemic neutrophil infiltration and MMP-9. These effects are not fully attributable to corticosterone. A, Ischemia increases brain MPO versus control (nonoperated and nontreated rats, and the contralateral hemisphere of normoglycemic rats; ***PϽ0.001). The increase is significantly higher in hyperglycemic than in normoglycemic rats (###PϽ0.001). B, Normoglycemic and hyperglycemic rats were treated with metyrapone or vehicle. Hyperglycemia enhances ischemia-induced MPO activity (**PϽ0.01). Metyrapone does not significantly reduce the effect of hyperglycemia. Values are optical density units/mg of protein, and are expressed as percentage of control. C, Hyperglycemia enhances MMP-9 brain content. D, Metyrapone does not significantly reduce MMP-9 induced by hyperglycemia in ischemic rats. std indicates gelatinase standard. E, Quantification of band intensity in the ipsilateral hemisphere of ischemic rats shows a significant (*PϽ0.01) increase of band a intensity in the hyperglycemic group. This effect was not fully prevented by metyrapone. F, Band b intensity remains unchanged after treatments. Values are optical density units and are expressed as percentage of control. Data were analyzed with 1-way ANOVA test followed by the Bonferroni test. N indicates Normoglycemic; H, Hyperglycemic; NϩMety, Normoglycemic and Metyrapone treatment; HϩMety, Hyperglycemic and Metyrapone treatment; NS, nonsignificant differences between the indicated groups.
Discussion
The present work shows that the exacerbated ischemic damage by acute hyperglycemia cannot be fully explained by enhanced neutrophil infiltration and plasma corticosteroids, and that hyperglycemia induces formation of O-linked glycoproteins in the ischemic brain. Nonetheless, we found indication that increased levels of plasma corticosteroids under hyperglycemia might negatively contribute to brain damage. Plasma corticosteroids were significantly involved in ischemic damage in rat global ischemia, [12] [13] [14] and they influenced the rate of hippocampal pyramidal cell disappearance after global ischemia in gerbils. 25 Here, in transient focal ischemia, metyrapone treatment did not show a clear benefit against hyperglycemic damage, suggesting that corticosterone is not the main determinant of exacerbated damage in this experimental model, conforming with previous studies. 26 Yet, metyrapone showed a tendency to attenuate the worsening effect of hyperglycemia on lesion volume, thus suggesting that corticosterone might further contribute to impair ischemic damage.
Metyrapone was reported to reduce infarct volume at 24 hours after permanent focal ischemia in normoglycemic spontaneously hypertensive rats. 27 In contrast, here we did not observe a significant protective effect of metyrapone in normotensive Sprague-Dawley rats. Differences with this previous study, such as strain of rats, 28 -29 blood pressure, 30 type of ischemia, and also dose of metyrapone, which in that study was 2ϫ higher, might account for discrepancies. In contrast to the view that corticoids worsen the outcome of ischemia, pretreatment with dexamethasone or administration of corticosterone (40 to 80 mg/kg) markedly reduced infarction after hypoxia-ischemia in young rats. 31 We also found that hyperglycemia exacerbated ischemic damage regardless of raises in neutrophil infiltration induced by this condition at 24 hours. Yet, negative effects of neutrophils are recognized, ie, they generate superoxide production and this effect increases with the duration of ischemia. 32 Our results do not exclude that neutrophils may have some contribution to ischemic damage, and that enhanced neutrophil infiltration might further contribute to worsening secondary damage at later times. 10 Hyperglycemia increased cerebral MMP-9 content after ischemia, which was reduced by preventing neutrophil infiltration. Furthermore, MMP-9 content was correlated with MPO activity, in agreement with previous results showing that infiltrated neutrophils are an important source of MMP-9 in the ischemic brain. 22 Here, we describe the occurrence of O-linked glycosylation in brain at 24 hours after acute hyperglycemia. O-Glycosylation can cause modification of Ser/Thr residues (O-GlcNAcylation) on a large number of signaling molecules, 19 and a putative role for transiently blocking residue phosphorylation has been proposed. 33 Notably, O-GlcNAcylation prevents Akt activation in response to insulin signaling, and it is increased in human coronary artery endothelial cells exposed to high glucose and in atherosclerotic plaques of diabetic patients. 15 Also, nuclear O-GlcNAcylation impairs cardiomyocite function under hyperglycemic conditions. 34 Further studies are needed to find out whether O-glycosylation is involved in exacerbating ischemic damage under hyperglycemia.
Summary
The results support that acute hyperglycemia intrinsically aggravates ischemic damage in transient MCAO in rats, besides plasma corticosterone and neutrophil infiltration. Nonetheless, our results indicate that corticosterone release might further exacerbate ischemic damage in hyperglycemic conditions. Various effects of high glucose might account for the intrinsic damaging effect of hyperglycemia. Among them, we identified O-linked glycosylation of proteins as a putative deleterious factor to be further investigated. 
